Cantor Fitzgerald analyst Li Watsek reiterates Aptose Biosciences (NASDAQ:APTO) with a Overweight and maintains $38 price target.
Cantor Fitzgerald Reiterates Overweight on Aptose Biosciences, Maintains $38 Price Target
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.